The company Affirma Biotech has opened a round of funding on the Capital Cell platform, both members of CataloniaBio & HealthTech. The biotech company hopes to raise 600,000 euros to confirm the efficacy of its new compounds as immune system activators for the treatment of severe viral and bacterial infections of the broad spectrum.

Affirma Biotech has carried out an intensive research programme in medicinal chemistry, which has resulted in the discovery of a family of new chemical compounds, orally available, that are immune system activators. These compounds have been granted patent protection until March 2023.

With the current round of funding, Affirma Biotech will complete the characterisation of the new molecules and carry out in vivo concept tests to confirm their activity in the indications of interest. Subsequently, it will seek a new round of around 5 million euros from venture capital funds specialised in the Biotech sector to carry out the pre-clinical and clinical development of its drugs, with the aim of licensing them to a pharmaceutical company once the clinical phase 2 has been completed.

Maribel Berges, CEO of the company, stresses the importance of developing new broad-spectrum therapies against viral infections "that contribute to solving increasingly urgent global health challenges.  We believe that our innovative approach will be key to the viability of the treatment of infectious diseases that currently do not have a complete medical solution". The company's goal is to start clinical trials within a maximum of two years.